This is an aggregated industry headline. Read the full story at BioPharma Dive →
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
By BioPharma Dive
· Jul 16, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Foundation Medicine has started the "Quality First" initiative to create awareness of how "not all cancer biom…
The WeekFierceBiotech ↗
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major…
The WeekPharmaceutical Technology ↗
MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.…